公开(公告)号：US08507206B2

公开(公告)日：2013-08-13

申请号：US11571532

申请日：2005-07-05

申请人： Mary P Lambert ,  Pauline T. Velasco ,  Lei Chang ,  Kirsten L. Viola ,  Sara J. Fernandez ,  Pascale N. Lacor ,  Daliya Khuon ,  Yuesong Gong ,  William L. Klein ,  Grant A. Krafft

发明人： Mary P Lambert ,  Pauline T. Velasco ,  Lei Chang ,  Kirsten L. Viola ,  Sara J. Fernandez ,  Pascale N. Lacor ,  Daliya Khuon ,  Yuesong Gong ,  William L. Klein ,  Grant A. Krafft

IPC分类号： G01N33/53

CPC分类号： C07K16/18 ,  C07K2317/76 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

摘要： Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.

摘要翻译： 本文公开了与淀粉样蛋白β（Abeta）的可溶性低聚物以高特异性结合的抗体以及使用这些抗体的方法。 抗体能够区分阿尔茨海默病（AD）和对照人脑提取物。 抗体鉴定AD脑切片中的内源性Aβ寡聚物，并且还结合培养的海马细胞上的Abeta寡聚物。 抗体中和溶液中产生的内源性Aβ低聚物和Abeta寡聚体。

公开(公告)号：US20080306074A1

公开(公告)日：2008-12-11

申请号：US11569122

申请日：2005-05-16

申请人： Pascale N. Lacor ,  Kirsten L. Viola ,  Mary P. Lambert ,  Yeusong Gong ,  Lei Chang ,  Pauline T. Velasco ,  Eileen H. Bigio ,  Maria C. Buniel ,  Sara J. Fernandez ,  Jasna Jerecic ,  Susan Catalano ,  Todd Pray ,  Ray Lowe ,  Grant A. Krafft ,  William L. Klein

发明人： Pascale N. Lacor ,  Kirsten L. Viola ,  Mary P. Lambert ,  Yeusong Gong ,  Lei Chang ,  Pauline T. Velasco ,  Eileen H. Bigio ,  Maria C. Buniel ,  Sara J. Fernandez ,  Jasna Jerecic ,  Susan Catalano ,  Todd Pray ,  Ray Lowe ,  Grant A. Krafft ,  William L. Klein

IPC分类号： A61K31/498 ,  G01N33/567 ,  A61P25/28

CPC分类号： C07K14/4711 ,  A61K31/495 ,  A61K38/00 ,  G01N33/5058 ,  G01N2800/2821

摘要： Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells.

摘要翻译： 本文公开和要求保护的是包含ADDL受体，相关组合物和相关方法的组合物。 ADDL受体通常但不限于，定位于神经元细胞的突触后密度（PSD）。 相关的组合物包括但不限于通过局限在突触后的密度（PSD）或其他方式的一种或多种受体影响ADDL与神经元细胞结合的积极或消极的化合物。 相关方法包括但不限于筛选通过一种或多种局限在突触后密度（PSD）或其他方式的受体而影响ADDL与神经元细胞结合的化合物的方法。 其他相关方法包括但不限于使用抑制，阻断或以其他方式干扰ADDL结合的组合物预防和治疗ADDL相关疾病，例如阿尔茨海默氏病，轻度认知障碍，唐氏综合征等。 位于神经元细胞突触后密度的一个或多个受体。